Who are TAS-118 plus Oxaliplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Xeloda, Irinotecan, 5FU, leucovorin, Oxaliplatin;Capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tas-118-plus-oxaliplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TAS-118 plus Oxaliplatin — Competitive Intelligence Brief

TAS-118 plus Oxaliplatin (TAS-118 plus Oxaliplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thymidylate synthase inhibitor. Area: Oncology.

phase 3 Thymidylate synthase inhibitor Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAS-118 plus Oxaliplatin (TAS-118 plus Oxaliplatin) — Taiho Pharmaceutical Co., Ltd.. TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAS-118 plus Oxaliplatin TARGET	TAS-118 plus Oxaliplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Thymidylate synthase inhibitor	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Xeloda	Xeloda	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed		Thymidylate synthase
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thymidylate synthase inhibitor class)

Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAS-118 plus Oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/tas-118-plus-oxaliplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab